Effect of Goserelin acetate on non-invasive indices of hepatic steatosis in women with endometriosis

Dimitrios A. Anastasilakis, Athanasios Anastasilakis, Athanasios D Anastasilakis, Athina Gkiomisi, Anastasios Semertzidis, Panagiotis Nikolakopoulos, Stergios Papachatzopoulos, Angelos Daniilidis, Aris Daniilidis, Dimitrios G Goulis, Antonis Goulas, Stergios A Polyzos
Endocrine · 2025 · vol. 91(1) , pp. 12 · doi:10.1007/s12020-025-04511-5 · PMID:41460405 · W7117453447
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-10 ⓘ

Goserelin treatment for endometriosis did not significantly alter non-invasive indices of hepatic steatosis or fibrosis in premenopausal women, despite expected changes in lipid profiles and insulin resistance.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

The study evaluated changes in non-invasive indices of hepatic steatosis and secondary fibrosis in premenopausal women with endometriosis undergoing pharmacologic menopause with goserelin, comparing measurements at baseline, 6 months during estrogen deficiency, and 6 months after discontinuation with a matched premenopausal control group. Indices of steatosis (HSI, TyG, TyG-BMI, TG/HDL, MetS-IR, DSI, FSI) and fibrosis (BARD) were calculated from clinical and laboratory data. Overall, most hepatic steatosis and fibrosis indices did not significantly change after goserelin, with the exception of MetS-IR showing an overall significant change that did not remain significant in pairwise comparisons after Bonferroni correction. The authors also note no datasets were generated for analysis and the study design was post-hoc, which limits causal interpretation. This paper is centrally about endometriosis — it specifically tests whether goserelin-induced estrogen deficiency alters non-invasive hepatic steatosis and fibrosis indices in women with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (52)

Source provenance

crossref
last seen: 2026-05-16T01:00:20.657101+00:00
europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-06-04T00:30:41.262415+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK